Navigation Links
Laser can spot illness before symptoms appear
Date:11/12/2007

It may not rank among the top 10 causes of death, but decompression sickness can be fatal. Instead of waiting for symptoms to appear, a University of Houston professor is developing a laser-based system that can diagnose the sickness in a matter of seconds.

Kirill Larin, assistant professor of biomedical engineering and mechanical engineering, is using a $400,000 grant from the U.S. Navy to develop the first optical non-invasive tool to test those most likely to suffer from decompression sickness, such as scuba divers, submariners and airplane pilots. Decompression sickness affects those who experience sudden, drastic changes in the air or water pressure surrounding their bodies. It can cause anything from joint pain known as the bends to seizure, stroke, coma and, in the most extreme cases, death.

Most of the time, decompression sickness isnt addressed until the person starts showing clinical symptoms, Larin said. It would be better, of course, to treat the problem before the symptoms appear. That would allow individuals to take the appropriate medical actions to reduce the side effects of decompression sickness.

Larins optical device can locate the presence of nitrogen gas or microbubbles in blood and tissues, which can restrict the flow of blood throughout the body and cause damage. Larin is developing the tool, which works much like an ultrasound machine, with Dr. Bruce Butler of the UT Health Science Center in Houston. Instead of getting readings using sound waves, however, Larins system uses light waves in the form of lasers that bounce back when they encounter resistance, thereby providing a high-resolution image.

The Navy could eventually use this technology on all divers or pilots returning to the surface. By shining the laser on one of these individuals, it would provide an image that would reveal the presence of any microbubbles in the blood or tissue all in a matter of seconds. If microbubbles are found, then medical steps,
'/>"/>

Contact: Ann Holdsworth
aholdsworth@uh.edu
713-743-8153
University of Houston
Source:Eurekalert

Page: 1 2

Related biology news :

1. LaserCard Corporation Announces Expansion of Middle East Project
2. Silicon Valley Technology Leaders LaserCard Corporation and Tesla Motors Sign LaserPass Secure Access Deal
3. New insights into how lasers cut flesh
4. Fine-tuning lasers to destroy blood-borne diseases like AIDS
5. Scientists tackle mystery mountain illness
6. Soy isoflavone may inhibit common gastrointestinal illness in infants
7. Brain cell growth diminishes long before old age strikes, animal study shows
8. New brain cells listen before they talk
9. Ohio scientists develop blue-blocking glasses to improve sleep and ADHD symptoms
10. Risk of common vaginal infection linked to preterm birth appears higher for blacks
11. Scientists identify embryonic stem cells by appearance alone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... – University of Utah engineers developed the first room-temperature ... produce electricity without needing to ignite the fuel. These ... electronics, off-grid power and sensors. , A study of ... Chemical Society journal ACS Catalysis . , Fuel ... between a fuel and an oxygen-rich source such as ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
(Date:11/3/2014)... ANGELES , Nov. 3, 2014  NeuroSigma ... -based life sciences company focused on commercialization ... system for the treatment of neurological and ... of Industrial Property has issued a Notice of ... patent application is co-owned by NeuroSigma and the ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... available in German . , Because Kapton ... lighter than glass typically used for PV, there are ... glass CdTe systems. High-speed and low-cost roll-to-roll deposition technologies ... cells on polymer film as substrates. The new polyimide ...
... able to evolve their way out of the threat posed by ... seashore animal. The work was published today (June 8) in the ... tide pool copepod Tigriopus californicus is found from Alaska ... animals showed little ability to evolve heat tolerance. "This is ...
... Electrical engineers have long been toying with the idea ... into electronic circuits. University of Pennsylvania researchers have developed ... operate in open-air environments, and, more important, have developed ... properties of these and similar devices. The research ...
Cached Biology News:Efficiency record for flexible CdTe solar cell due to novel polyimide film 2Can evolution outpace climate change? 2Penn researchers develop biological circuit components, new microscope technique for measuring them 2Penn researchers develop biological circuit components, new microscope technique for measuring them 3
(Date:11/22/2014)... MA (PRWEB) November 21, 2014 ... key investors will gather on December 3rd at ... Biotech Conferences series. GeneticRx will take place at ... Medical School and will discuss the present and ... therapy, exon skipping, and gene editing—as well as ...
(Date:11/22/2014)... November 21, 2014 RURO, Inc., ... provider, has released Limfinity® version 5.1.4. , RURO’s ... of Limfinity® than ever in RURO’s 8 year ... minority framework enhancement. Limfinity® version 5.1.4 is the ... and beyond bug fixes! , Limfinity® 5.1.4 release ...
(Date:11/22/2014)... 2014 The “Chiral Chromatography Columns ... Material (Metal, Glass, Plastic), by Application [GC, LC ... Forecast to 2018” analyses and studies the major ... America, Europe, Asia, and Rest of the World. ... figures spread through 135 pages and in-depth TOC ...
(Date:11/22/2014)... 2014  The element of surprise has been a ... strike without warning. Until now, epidemiologists had nothing to ... outbreak, resulting in suboptimal responses to both the H1N1 ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... because virus gene structural changes have been found that ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5Viruses' Advantage of Surprise is Lost 2
... , SAN DIEGO, Calif., July ... and its subsidiary Tissue Repair Company (TRC) today provided an ... study and announced plans to provide detailed safety and efficacy ... September. The MATRIX trial, a prospective, randomized, double-blind, placebo-controlled ...
... , , SUNRISE, Fla., July ... to delivering intelligent devices and biologics that help monitor, diagnose and ... FDA cleared a phase I clinical trial for MyoCell SDF-1 (Stromal ... REGEN trial will enroll 15 patients in a multicenter, randomized, dose ...
... , , CINCINNATI, July 27 ... full-service clinical research organization, today appointed Stephen Cutler, PhD, as ... (COO) effective immediately. Dr. Cutler brings to Kendle more than ... the CRO and biopharmaceutical industries to position the Company for ...
Cached Biology Technology:Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 2Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 3Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 4Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 5United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 2United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 3United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 4Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer 2Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer 3